Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

5.7K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.7K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

236
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia-selective targeting of eEF1A1: A promising therapeutic strategy for triple-negative breast cancer.

Acta pharmaceutica Sinica. B·2026
Same authorSame journal

Development and evaluation of a novel deuterated fluorine-18 PET tracer for MAO-B imaging.

American journal of nuclear medicine and molecular imaging·2026
Same author

Novel 1‑Phenyl-2,3-dihydroquinazolin-4(1H)-one Derivatives as Na<sub>v</sub> 1.8 Voltage-Gated Sodium Channels Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Pyrido[4,3‑<i>d</i>]pyrimidine Derivatives as Kirsten Rat Sarcoma (KRAS) G12C Potential Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment.

ACS medicinal chemistry letters·2026
Same author

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

<sup>18</sup>F-Flurpiridaz PET in myocardial perfusion imaging: comparing effectiveness against traditional tracers.

American journal of nuclear medicine and molecular imaging·2026
Same journal

Positron emission tomography imaging of T-cell activity in cardiovascular disease and its emerging role in imaging adaptive immunity.

American journal of nuclear medicine and molecular imaging·2026
Same journal

Calibration and prediction of results after failed injection in SPECT renal dynamic imaging.

American journal of nuclear medicine and molecular imaging·2026
Same journal

<sup>18</sup>F-NaF and <sup>18</sup>F-FDG PET/CT imaging of spinal instrumentation: case report and review of the literature.

American journal of nuclear medicine and molecular imaging·2026
Same journal

Bladder activity of different PSMA PET radioligands and impact of furosemide.

American journal of nuclear medicine and molecular imaging·2026
See all related articles

Related Experiment Video

Updated: Sep 14, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K

Trop2-targeted immunoPET ligands.

Steven H Liang1

  • 1Department of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, United States.

American Journal of Nuclear Medicine and Molecular Imaging
|July 21, 2025
PubMed
Summary
This summary is machine-generated.

Trop2, a tumor biomarker, is targeted by immunoPET imaging agents. These agents, derived from antibodies and nanobodies, reveal Trop2

Keywords:
Trophoblast cell-surface antigen 2 (Trop2)immunoPET ligandin vivo imagingnanobodytumor

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Sep 14, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Oncology
  • Biomarkers
  • Molecular Imaging

Background:

  • Trop2 is frequently overexpressed across diverse tumor types.
  • Trop2 serves as a significant biomarker in cancer research and clinical practice.

Purpose of the Study:

  • To explore the utility of targeted immunoPET ligands for visualizing Trop2 expression.
  • To assess the potential of immunoPET in improving cancer diagnosis, staging, and therapeutic strategies.

Main Methods:

  • Development of targeted immunoPET ligands based on Trop2 monoclonal antibodies and nanobodies.
  • Utilizing these ligands to map the heterogeneous expression patterns of Trop2 within tumors.

Main Results:

  • ImmunoPET ligands effectively visualize the landscape of Trop2 expression in tumors.
  • Demonstrated heterogeneity in Trop2 expression across different tumor sites.

Conclusions:

  • Targeted immunoPET imaging targeting Trop2 offers a promising approach for cancer visualization.
  • This technology has significant potential to enhance the accuracy of cancer diagnosis, staging, and therapy selection.